Study on super human dried amniotic membrane manufacture technology aiming at the manufacture of new materials for the regenerative therapy

2015 Fiscal Year Final Research Report

• Project/Area Number: 25460647
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Applied pharmacology
• Research Institution: University of Toyama
• Principal Investigator: Okabe Motonori 富山大学, 大学院医学薬学研究部(医学), 助教 (60283066)
• Co-Investigator(Kenkyū-buntansha): 吉田 淑子 富山大学, 大学院医学薬学研究部(医学), 准教授 (00171421) ; 相古 千加 富山大学, 大学院医学薬学研究部(医学), 助教 (10523889) ; 二階堂 敏雄 富山大学, 学内共同利用施設等, 理事・副学長 (50180568) ; 野村 義宏 東京農工大学, 農学部, 教授 (10228372) ; 林 京子 中部大学, 付置研究所, 研究員 (60110623)
• Co-Investigator(Renkei-kenkyūsha): MIZUTA SYOUSHI 福井県立大学, 生物資源学, 准教授 (30254246) ; DOKI YOSHINORI 富山大学, 大学院医学薬学研究部(医学), 講師 (90303221)
• Project Period (FY): 2013-04-01 – 2016-03-31
• Keywords: ヒト組織利用研究 / ハイパードライヒト乾燥羊膜 / 抗生物質 / 抗菌効果 / 定量 / 国際特許

Outline of Final Research Achievements

The human amniotic membrane (AM) has been widely used in ophthalmic surgery. However, it has never been explored that AM is effective for the release of impregnated drugs.
Hyperdry-AM (HD-AM), glutaraldehyde cross-linked HD-AM (Glu HD-AM) and a solvent of poly-N-p-vinylbenzyl-D-lactonamide (PVLA) were all found not to cause irritation to the rabbit eye. Residual glutaraldehyde in Glu HD-AM was about 40 ppm (dry-weight basis). HD-AM (ACV/PVLA HD-AM) loaded Acyclovir (ACV; hydrophobic medicine) containing PVLA-bearing nanospheres (ACV/PVLA) was more effective against a herpes simplex virus-1 (HSV-1) eye infection model and its efficacy was dose- and volume-dependent.
A combination of HD-AM and PVLA can be working as drug delivery system that may be possible to controlle the release of hydrophobic medicines.

Free Research Field

境界医学、応用薬理学、ヒト組織利用研究、再生医学、